SeeTreat to Launch ART.1 to Support Adaptive Radiotherapy at ESTRO 2025
Summary
"Adaptive radiotherapy has traditionally been complex, costly, and limited to well-resourced centers," said Trang Nguyen, CEO and founder of SeeTreat. "We designed ART.1 to perform background analysis of every fraction, prioritizing major deviation, and give the clinical team a second set of eyes—without adding to the workload, resources or time." What Makes ART.1 Different: Saving Days, Not Hours ART.1 integrates seamlessly with existing linear accelerators and treatment planning systems, and automates the most resource-intensive steps in the adaptive workflow: • Analyzes every structure for every fraction using synthetic CTs, daily dose calculation, and deformable contour propagation • Sends alerts based on protocol thresholds for dosimetric and volumetric changes to treatment volumes and organs at risk • Prioritizes patients for review—reducing unnecessary checks and freeing up staff • Minimizes manual work by automating and prioritizing your adaptive workload With detection, analysis, and alerts built into a single workflow, ART.1 reduces time to inform a decision from days to minutes—empowering the clinical team to act faster, with greater confidence. Its software-only model fits into existing infrastructure, making it ideal for regional and community cancer centers where resources are tight but precision matters. The company builds intelligent software that automates the most difficult parts of the adaptive workflow— helping more clinics deliver adaptive-quality care, every day.